8-K: Adtalem Global Education Reports Strong FY25, Boosts Revolver

Adtalem Global Education Inc. announced exceptional fiscal year 2025 results with significant revenue and adjusted EPS growth, alongside an amendment to its credit agreement increasing its revolving facility to $500 million and extending its maturity.

Summary

• Adtalem Global Education Inc. reported fiscal year 2025 revenue of $1,788.3 million, an increase of 12.9% year-over-year.
• Diluted earnings per share for fiscal year 2025 was $6.18, up 82.3% from $3.39 in the prior year, while adjusted diluted EPS grew 33.1% to $6.67.
• Adjusted EBITDA for fiscal year 2025 reached $459.7 million, a 21.8% increase year-over-year, with an adjusted EBITDA margin of 25.7%.
• Total student enrollment for the fourth quarter of fiscal year 2025 was 91,780, representing a 10.2% increase year-over-year.
• Chamberlain University achieved its tenth consecutive quarter of total enrollment growth, up 5.8% year-over-year, reaching a record of over 40,500 enrolled students for FY25.
• Walden University recorded its eighth consecutive quarter of total enrollment growth, up 15.0% year-over-year, with over 48,500 enrolled students for FY25.
• Medical and Veterinary schools sustained total enrollment growth of 1.0% year-over-year, with approximately 5,000 students enrolled on average for FY25.
• The company amended its credit agreement to increase available commitments under its revolving facility by $100.0 million, resulting in aggregate outstanding commitments of $500.0 million.
• The maturity and commitment termination date of the revolving facility has been extended to August 6, 2030.
• Pricing on drawn revolving loans has been reduced, offering SOFR plus an applicable margin ranging from 2.25% to 3.00% or an alternate base rate plus an applicable margin ranging from 1.25% to 2.00%, depending on the company's net first lien leverage ratio.
• Adtalem repurchased $211 million of shares in fiscal year 2025, completing a prior authorization, and the Board authorized a new $150 million share repurchase program through May 2028.
• The company repriced its $253 million Term Loan B on August 21, 2024, reducing the interest rate by 75 basis points, and repaid $100 million of the outstanding balance on January 17, 2025.
• Net leverage stood at 0.8x as of June 30, 2025.

Sentiment

Score: 9

Explanation: The company reported exceptional financial results for FY25, demonstrating strong growth in revenue, EPS, and EBITDA. Significant student enrollment increases across all segments highlight robust demand. The credit agreement amendment enhances financial flexibility with increased capacity and reduced borrowing costs. A new share repurchase authorization further signals confidence in future performance and commitment to shareholder value. The outlook for FY26 also projects continued strong growth.

Positives

• Exceptional fiscal year 2025 financial results with significant growth in revenue (12.9%), diluted EPS (82.3%), and adjusted EPS (33.1%).
• Strong adjusted EBITDA growth of 21.8% and an improved adjusted EBITDA margin of 25.7% for FY25.
• Consistent and robust total student enrollment growth across all segments, including Chamberlain (5.8%), Walden (15.0%), and Medical and Veterinary (1.0%) for Q4 FY25.
• Increased financial flexibility with the revolving facility expanded by $100 million to $500 million and an extended maturity date to August 6, 2030.
• Reduced interest rate on drawn revolving loans and the repricing of the Term Loan B by 75 basis points, leading to lower borrowing costs.
• Demonstrated commitment to shareholder returns through the completion of a $211 million share repurchase program and authorization of a new $150 million program.
• Strategic partnerships, such as the Aspiring Nurse Program with SSM Health, are creating direct employment pathways and addressing critical healthcare workforce needs.
• Academic recognition for Walden and Chamberlain Universities with the 'Opportunity Colleges and Universities' designation and CSWE accreditation for Walden's DSW program.

Risks

• The revolving facility maturity date of August 6, 2030, is subject to an earlier springing maturity if the First Lien Notes or Term Loans are not refinanced, redeemed, or repaid in full 91 days prior to their applicable stated maturity date.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, as disclosed in Item 1A. Risk Factors of the company's most recent Annual Report on Form 10-K.

Future Outlook

Adtalem Global Education initiated guidance for fiscal year 2026, projecting revenue in the range of $1,900 million to $1,940 million, representing approximately 6.0% to 8.5% growth year-over-year. Adjusted earnings per share are expected to be in the range of $7.60 to $7.90, indicating approximately 14.0% to 18.5% growth year-over-year.

Management Comments

• Steve Beard, chairman and chief executive officer of Adtalem Global Education, stated: 'Fiscal 2025 marked a defining moment for Adtalem—an inflection point that demonstrated the strength and scaled ability of our Growth with Purpose strategy. We delivered strong financial results while deepening our impact—graduating more healthcare professionals into roles where they’re urgently needed. Our disciplined investments and student outcomes, coupled with strategic partnerships, are creating repeatable high return pathways from education to employment. With a resilient operating model and growing momentum, we are well-positioned to sustain performance and deliver long-term value for our students, shareholders and the U.S. healthcare system.'

Industry Context

Adtalem Global Education, as a leading healthcare educator, is actively addressing critical healthcare workforce needs in the U.S. through innovative programs and strategic partnerships. Initiatives like the Aspiring Nurse Program with SSM Health and the MAGIC partnership with Massachusetts General Hospital Institute of Health Professions demonstrate a proactive approach to aligning education with industry demands, particularly in areas like AI digital transformation in healthcare. The company's focus on strong student outcomes and employment pathways positions it favorably within the evolving healthcare education landscape.

Comparison to Industry Standards

• Chamberlain University and Walden University earned the prestigious 'Opportunity Colleges and Universities' designation in the 2025 Carnegie Classification, a selective recognition awarded to only 16% of assessed institutions, confirming their ability to serve broad student populations while delivering strong economic outcomes.
• Walden University's Doctor of Social Work (DSW) program achieved accreditation by the Council on Social Work Education (CSWE), making it one of only four DSW programs in the U.S. to receive this recognition, validating its quality and the professional excellence of its graduates.
• The collaboration between American University of the Caribbean School of Medicine (AUC) and Massachusetts General Hospital Institute of Health Professions (MGHIHP) to create the MAGIC partnership places AUC students and alumni at the forefront of the AI digital transformation in healthcare, shaping the future of medicine, which is a forward-thinking move compared to traditional medical education models.

Corporate Governance

Stakeholder Impact

• Shareholders: Benefit from strong financial performance, increased earnings per share, and a new share repurchase authorization, indicating management's confidence and commitment to returning capital.
• Lenders: The amended credit agreement provides new terms for the revolving facility, including an extended maturity and revised pricing, while reaffirming existing guarantees and security interests.
• Students: Benefit from continued enrollment growth, new strategic partnerships creating employment pathways (e.g., Aspiring Nurse Program), and academic recognitions (e.g., Carnegie Classification, CSWE accreditation) that enhance program quality and career prospects.
• Employees: The company's 'Growth with Purpose' strategy and focus on operational efficiency may impact workforce planning, though no specific new changes were announced in this filing beyond general restructuring expenses mentioned in non-GAAP adjustments.

Next Steps

• Continue executing the 'Growth with Purpose' strategy to sustain performance and deliver long-term value.
• Work towards achieving the fiscal year 2026 guidance for revenue ($1,900 million to $1,940 million) and adjusted EPS ($7.60 to $7.90).
• Leverage strategic partnerships, such as the Aspiring Nurse Program and MAGIC partnership, to deepen impact and create employment pathways.
• Monitor the Net First Lien Leverage Ratio to optimize the Applicable Margin for 2025 Refinancing Revolving Facility Loans, as per the Pricing Grid.

Key Dates

Recommendation

Adtalem Global Education delivered exceptional fiscal year 2025 results, significantly outperforming in revenue, adjusted EPS, and adjusted EBITDA. The company's strategic initiatives have driven robust student enrollment growth across all segments, indicating strong underlying business health and market demand for its healthcare education programs. The amendment to the credit agreement, which increases the revolving facility, extends its maturity, and reduces borrowing costs, substantially improves the company's financial flexibility and capital structure. Furthermore, the commitment to shareholder returns through a new $150 million share repurchase authorization, coupled with a positive fiscal year 2026 outlook projecting continued strong growth, makes Adtalem Global Education a compelling 'strong buy' for investors seeking exposure to a well-managed and growing leader in the healthcare education sector.

Keywords

Adtalem Global Education, ATGE, Healthcare Education, Financial Results, Credit Agreement, Revolving Facility, Student Enrollment, Earnings Per Share, EBITDA, Share Repurchase, Corporate Finance, Debt Refinancing, Chamberlain University, Walden University, Medical Education, Veterinary Education